Fig. 1
From: India’s ban on antimicrobial fixed-dose combinations: winning the battle, losing the war?
Trends in sales of banned antimicrobial fixed-dose combination (FDC) formulations between January 2018 and December 2019. The graph is based on monthly sales volumes of each product (across brands) expressed in standard units (i.e., doses) as obtained from IQVIA Inc. The ban on select antimicrobial FDCs was introduced in India in September 2018. Note: Ofloxacin+metronidazole suspension was not banned and is presented only for comparison with banned formulations of ofloxacin+ornidazole suspension